ANALIZE MEDICALE DE LABORATOR
Aici gasiti analizele medicale grupate pe categorii precum si detalii generale si specifice pentru categoriile respective.
Selectati o categorie din lista de mai jos:
Solutie antistress!
Construieste poduri :)
Prinde pisica neagra :)
Boston Scientific Announces First European Implants Of New Devices To Treat Heart Failure And Sudden Cardiac Death
Boston Scientific
Corporation (NYSE: BSX) announced the first European implants of its
COGNIS(TM) cardiac resynchronization therapy defibrillator (CRT-D) and
TELIGEN(TM) implantable cardioverter defibrillator (ICD). Physicians began
performing implants earlier this week. Forty implants have been performed
in 14 hospitals in six countries.
When choosing a high-energy device, physicians often must make
trade-offs among device size, battery longevity and features. The COGNIS
CRT-D and the TELIGEN ICD are designed to eliminate those compromises. They
are among the world's smallest and thinnest high-energy devices at 32.5 cc
and 31.5 cc respectively, while less than 10 mm thick. They offer features
based on significant engineering advances, including extended battery
longevity, self- correcting software and improved programming technology.
These devices are built on an entirely new technology platform and are the
result of a multi- year research and development effort to provide
physicians enhanced clinical options for their patients.
The COGNIS CRT-D and TELIGEN ICD received CE Mark last month. This
week's implants represent the beginning of the market launch in Europe. The
Company plans to build to a full launch in Europe and other international
markets in the second quarter.
"The COGNIS CRT-D offers extended battery longevity and several new
features that will help me better manage my heart failure patients," said
Poul-Erik Bloch-Thomsen, M.D., Gentofte Hospital, Hellerup, Denmark. "For
example, the SmartDelay(TM) feature recommends programmable device
settings, which enable me to tailor individualized pacing therapies."
"The TELIGEN ICD has comprehensive programming options that address the
requirements of both physicians and patients," said Lieselotte van Erven,
M.D., Leiden University Medical Center, Leiden, The Netherlands. "The
device offers me flexibility for delivering defibrillation to my patients
and helps ensure that the right therapy is delivered at the appropriate
time."
"These devices are further evidence of our commitment to research and
development, and they are the latest indications of how we have refocused
our cardiac rhythm management business on the needs of physicians and
patients," said Jim Tobin, President and Chief Executive Officer of Boston
Scientific.
The COGNIS CRT-D and the TELIGEN ICD are pending approval by the U.S.
Food and Drug Administration and are not available for sale in the United
States.
Boston Scientific is a worldwide developer, manufacturer and marketer
of medical devices whose products are used in a broad range of
interventional medical specialties. For more information, please visit:
http://www.bostonscientific.com.
Cautionary Statement Regarding Forward Looking Statements
This press release contains forward-looking statements within the
meaning of Section 21E of the Securities Exchange Act of 1934.
Forward-looking statements may be identified by words like "anticipate,"
"expect," "project," "believe," "plan," "estimate," "intend" and similar
words. These forward- looking statements are based on our beliefs,
assumptions and estimates using information available to us at the time and
are not intended to be guarantees of future events or performance. These
forward-looking statements include, among other things, statements
regarding our product performance, regulatory approval of our products, new
product launches, competitive offerings, our growth strategy, and our
market position. If our underlying assumptions turn out to be incorrect, or
if certain risks or uncertainties materialize, actual results could vary
materially from the expectations and projections expressed or implied by
our forward-looking statements. These factors, in some cases, have affected
and in the future (together with other factors) could affect our ability to
implement our business strategy and may cause actual results to differ
materially from those contemplated by the statements expressed in this
press release. As a result, readers are cautioned not to place undue
reliance on any of our forward-looking statements.
Factors that may cause such differences include, among other things:
future economic, competitive, reimbursement and regulatory conditions; new
product introductions; demographic trends; intellectual property;
litigation; financial market conditions; and, future business decisions
made by us and our competitors. All of these factors are difficult or
impossible to predict accurately and many of them are beyond our control.
For a further list and description of these and other important risks and
uncertainties that may affect our future operations, see Part I, Item 1A-
Risk Factors in our most recent Annual Report on Form 10-K filed with the
Securities and Exchange Commission, which we may update in Part II, Item 1A
- Risk Factors in Quarterly Reports on Form 10-Q we have filed or will file
thereafter. We disclaim any intention or obligation to publicly update or
revise any forward- looking statements to reflect any change in our
expectations or in events, conditions, or circumstances on which those
expectations may be based, or that may affect the likelihood that actual
results will differ from those contained in the forward-looking statements.
This cautionary statement is applicable to all forward-looking statements
contained in this document.
Boston Scientific Corporation
http://www.bostonscientific.com
Boston ºtiinþifice anunþã prima European de implanturi de noi dispozitive la tratamentul insuficienþei cardiace ºi de moarte subitã cardiacã - Boston Scientific Announces First European Implants Of New Devices To Treat Heart Failure And Sudden Cardiac Death - articole medicale engleza - startsanatate